SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Lowers Price Target to $68
SVB Leerink analyst Roanna Ruiz maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform and lowers the price target from $80 to $68.
Enanta Pharmaceuticals Q1 EPS $(1.48) Misses $(1.09) Estimate, Sales $27.65M Beat $27.44M Estimate
Enanta Pharmaceuticals (NASDAQ:ENTA) reported quarterly losses of $(1.48) per share which missed the analyst consensus estimate of $(1.09) by 35.78 percent. This is a 260.98 percent decrease over losses of $(0.41) per
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell
• Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.
What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals
Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) within the last quarter:
SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Lowers Price Target to $80
SVB Leerink analyst Roanna Ruiz maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform and lowers the price target from $85 to $80.
Oppenheimer Maintains Perform on Enanta Pharmaceuticals, Raises Price Target to $73
Oppenheimer analyst Jay Olson maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Perform and raises the price target from $55 to $73.
56 Biggest Movers From Yesterday
Gainers
Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).
SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Lowers Price Target to $85
SVB Leerink analyst Roanna Ruiz maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform and lowers the price target from $92 to $85.
Earnings Scheduled For November 22, 2021
Companies Reporting Before The Bell
• Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.